Plus Therapeutics (FRA:XMP1) Moat Score: 3/10 (As of Jun. 26, 2026)


FRA:XMP1 Plus Therapeutics Inc FRA:XMP1
22 GF Score
Price €3.38
! 2 Warning Signs
View Full Analysis

What is Plus Therapeutics Moat Score?

Plus Therapeutics FRA:XMP1 -3.01% 22 Moat Score is 3 as of Jun. 26, 2026. GuruFocus rates FRA:XMP1 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,404 Biotechnology companies, Plus Therapeutics ranks better than 75.5% on this metric.

Plus Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Plus Therapeutics has No Moat: Plus Therapeutics Inc operates in a competitive biotech industry with limited intellectual property and high R&D costs. The lack of significant market share or customer loyalty results in weak competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Plus Therapeutics might have No Moat - Very weak/transient advantages.

Plus Therapeutics  (FRA:XMP1) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Plus Therapeutics Moat Score Related Terms

FRA:XMP1 vs GRCE, NNVC, ATNM: Moat Score Comparison

For the Biotechnology subindustry, Plus Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Plus Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's Moat Score falls into.


FRA:XMP1
22GF Score
Plus Therapeutics Inc FRA:XMP1
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Plus Therapeutics (FRA:XMP1) has a Moat Score of 3 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Plus Therapeutics ranks #344 out of 1404 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Plus Therapeutics' Moat Score too high?
Plus Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Plus Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Plus Therapeutics ranks #344 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Plus Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' Moat Score compare to GRCE and NNVC?
According to the Biotechnology industry distribution chart, Plus Therapeutics ranks #344 out of 1404 companies for Moat Score. This places Plus Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Plus Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Plus Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Plus Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (FRA:XMP1) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Plus Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Plus Therapeutics (FRA:XMP1), the current Moat Score is 3 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plus Therapeutics Business Description

Other Exchanges PSTV:USA
Address 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
22GF Score

Get the complete analysis for FRA:XMP1

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.38
Price